David D Chang insider trades: Allogene Therapeutics (ALLO) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
21 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | ALLO | ↓ Sell | 47,763 | $2.47 | $118K | Direct | Mar 18, 2026 (2d) |
| Feb 2, 2026 | ALLO | ↓ Sell | 95,269 | $1.80 | $171K | Direct | Feb 4, 2026 (2d) |
| Mar 14, 2025 | ALLO | ↓ Sell | 46,668 | $1.96 | $91K | Direct | Mar 18, 2025 (4d) |
| Feb 3, 2025 | ALLO | ↓ Sell | 46,003 | $1.68 | $77K | Direct | Feb 5, 2025 (2d) |
| Mar 15, 2022 | ALLO | ↓ Sell | 23,648 | $7.65 | $181K | Direct | Mar 17, 2022 (2d) |
| Mar 15, 2021 | ALLO | ↓ Sell | 20,513 | $38.57 | $791K | Direct | Mar 17, 2021 (2d) |
| Mar 16, 2020 | ALLO | ↓ Sell | 20,335 | $19.31 | $393K | Direct | Mar 18, 2020 (2d) |
| Oct 15, 2018 | ALLO | ↑ Buy | 40,000 | $18.00 | $720K | Direct | Oct 17, 2018 (2d) |
| Sep 25, 2017 | KITE | ↓ Sell | 7,927 | $179.66 | $1.4M | Direct | Sep 27, 2017 (2d) |
| May 1, 2017 | KITE | ↓ Sell | 20,000 | $82.09 | $1.6M | Direct | May 3, 2017 (2d) |
| Apr 3, 2017 | KITE | ↓ Sell | 20,000 | $81.54 | $1.6M | Direct | Apr 4, 2017 (1d) |
| Mar 1, 2017 | KITE | ↓ Sell | 60,000 | $79.16 | $4.7M | Direct | Mar 2, 2017 (1d) |
| Dec 20, 2016 | KITE | ↓ Sell | 1,788 | $50.86 | $91K | Direct | Dec 22, 2016 (2d) |
| Nov 10, 2015 | KITE | ↓ Sell | 30,800 | $80.02 | $2.5M | Direct | Nov 12, 2015 (2d) |
| Nov 2, 2015 | KITE | ↓ Sell | 7,700 | $71.08 | $547K | Direct | Nov 4, 2015 (2d) |
| Oct 1, 2015 | KITE | ↓ Sell | 7,700 | $55.11 | $424K | Direct | Oct 2, 2015 (1d) |
| Sep 8, 2015 | KITE | ↓ Sell | 7,700 | $55.00 | $424K | Direct | Sep 8, 2015 (0d) |
| Aug 3, 2015 | KITE | ↓ Sell | 7,700 | $72.11 | $555K | Direct | Aug 4, 2015 (1d) |
| Jul 1, 2015 | KITE | ↓ Sell | 7,700 | $61.92 | $477K | Direct | Jul 2, 2015 (1d) |
| Jun 15, 2015 | KITE | ↓ Sell | 7,700 | $56.98 | $439K | Direct | Jun 17, 2015 (2d) |
| Jun 25, 2014 | KITE | ↑ Buy | 4,000 | $17.00 | $68K | Direct | Jun 17, 2015 (357d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ALLO insiders
Open-market trades in the last 12 months
About David D Chang's insider trades
David D Chang is President and CEO at Allogene Therapeutics (ALLO). Since Jun 25, 2014, David has reported 2 open-market purchases worth $788K and 19 sales worth $16.7M on SEC Form 4. In the last 12 months: 2 sales ($289K).
Their filings also include grants and awards (13 filings), option exercises (11 filings), other transactions (11 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALLO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.